Table 2.
Significantly upregulated/downregulated genes in clinical T1 stage with or without aggressive characteristics (metastasis, recurrence, or cancer-specific death).
| Upregulated | ||||||
|---|---|---|---|---|---|---|
| Gene Symbol | Gene Title | FPKM (Mean ± SD) | Log2 Fold Change | p-Value a | Adjusted p b | |
| RCC with Aggressive Characteristics | RCC without Aggressive Characteristics | (With Aggressive/without Aggressive Characteristics) | ||||
| MOCOS | Molybdenum cofactor sulfurase | 16.76 ± 15.41 | 1.40 ± 1.29 | +3.77 | 9.29 × 10−6 | 1.66 × 10−2 |
| RGPD8 | RANBP2-like and GRIP domain containing 8 | 41.49 ± 35.62 | 6.51 ± 5.38 | +2.78 | 3.67 × 10−5 | 4.59 × 10−2 |
| BAIAP2L1 | BAI1 associated protein 2 like 1 | 7.05 ± 3.39 | 2.18 ± 1.28 | +1.87 | 2.18 × 10−6 | 7.98 × 10−3 |
| DDX11 | DEAD/H-box helicase 11 | 31.95 ± 13.09 | 14.25 ± 5.18 | +1.32 | 2.55 × 10−6 | 7.98 × 10−3 |
| Downregulated | ||||||
| Gene Symbol | Gene Title | FPKM (Mean ± SD) | Log2 Fold Change | p-Value a | Adjusted pb | |
| RCC with Aggressive Characteristics | RCC without Aggressive Characteristics | (With Aggressive/without Aggressive Characteristics) | ||||
| SLC16A9 | Solute carrier family 16 member 9 | 2.13 ± 2.51 | 11.90 ± 8.48 | −2.41 | 5.91 × 10−6 | 1.48 × 10−2 |
| FRAS1 | Fraser extracellular matrix complex subunit 1 | 3.15 ± 3.80 | 13.66 ± 6.60 | −2.12 | 4.37 × 10−8 | 5.47 × 10−4 |
| NPR3 | Natriuretic peptide receptor 3 | 3.22 ± 3.37 | 12.53 ± 7.84 | −1.88 | 3.61 × 10−5 | 4.59 × 10−2 |
| AQP1 | Aquaporin 1 (Colton blood group) | 11.02 ± 11.86 | 36.80 ± 17.38 | −1.63 | 1.73 × 10−5 | 2.71 × 10−2 |
| TMEM38B | Transmembrane protein 38B | 2.74 ± 1.81 | 8.07 ± 2.70 | −1.47 | 1.21 × 10−6 | 7.57 × 10−3 |
| PRUNE2 | Prune homolog 2 | 19.10 ± 9.42 | 49.39 ± 15.65 | −1.24 | 8.48 × 10−6 | 1.66 × 10−2 |
FPKM, fragments per kilobase of exon per million fragments mapped; RCC, renal cell carcinoma; SD, standard deviation; a p-values by nbiomTest function in DESeq2; b Adjusted p-values by the Benjamini–Hochberg algorithm.